TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: verbal learning and memory impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant Stability Quotient (ISQ) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft tissue reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Emotional exhaustion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall burnout
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression prevalence in TPL women
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reductions in posttraumatic stress disorder symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in shame
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: daily glycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: morbidity (Sepsis-related Organ Failure Assessment score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative flank pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total narcotic use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Daily physical exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthier diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restriction by angina in everyday activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cardiovascular complications
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of CBD coadministration
Endpoint domain: Adverse events/effects
Primary endpoint: Mean duration of the operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Postoperative discomfort
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient benefit from operation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total vitamin B6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LDQ scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: days to use rescue drug
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: O2max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eradication rates of S10 and T14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyspeptic symptom release
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucosal chronic inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CVD screening for blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CVD screening for cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CVD screening for glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: self‐estimated level of physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: performance in the one‐leg stance test for the right leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: co‐ordination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in left ventricular end-diastolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Symptoms during left ventriculogram
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Detection of liver cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean adherence score
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Frequency of BZD prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: SNOT-16 score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: MCT (Mucociliary Transport time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inflammation reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adhesion probability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of moderate hypothermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: axillary temperatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental development index
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: HUTT-based effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence rate of syncope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in PON activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in AuAb-oxLDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in HDL-cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of positive patch test reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Integrated plasma pancreatic polypeptide response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Effectiveness of moxidectin in preventing heartworm development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Net fluid loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse/Breakthrough
Endpoint domain: Adverse events/effects
Primary endpoint: averted disability-adjusted life-years (DALYs)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adverse events prevalence
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum heart rate increase (Emax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma regadenoson concentration causing a 50% increase in maximum heart rate (EC50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage of subjects undergoing secondary surgeries
Endpoint domain: Adverse events/effects
Primary endpoint: pupillary responsiveness to light stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAMD scores reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SERS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased suicide risk
Endpoint domain: Mortality/survival
Primary endpoint: massive clotting rate
Endpoint domain: Adverse events/effects
Primary endpoint: mean heparin doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: global mean death rate
Endpoint domain: Mortality/survival
Primary endpoint: Cognitive performance deficits in speed, consistency, and efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quadriceps peak torque deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Extension deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: histologic improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resolution of steatohepatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in nonalcoholic fatty liver disease Activity Score (NAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histologic scores of the tendon-bone interface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: misclassification error rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of Atrial Fibrillation (AF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: P dispersion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Timely referral to social workers
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Need for shunting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Composite score for mental development and motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proton pump inhibitor prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: General practitioner consultations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Symptoms measured on the Leeds Dyspepsia Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: point-prevalence smoking abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of days to bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance walked post-surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assistance required for transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discharge directly home
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Response of GBM to antineoplastic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative surgical-site infections
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative nonsurgical-site infections
Endpoint domain: Adverse events/effects
Primary endpoint: Successful establishment of a comprehensive tumour molecular profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of target lesion revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Average nausea score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-anesthesia care unit (PACU) stay duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Patient satisfaction with control of PONV
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of participants who had sexual intercourse
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Start of tobacco use
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of women with HAI titers >1:40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in mucosa-associated microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: myocardial blush grade 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: complete ST-segment resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NPI‐NH Psychosis Subscale improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI‐S improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BPRS Total improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-stent volume obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total lung capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Partial pressure of arterial oxygen at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Response to acupuncture
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Overall symptomatic hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Nocturnal symptomatic hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: BMI loss at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Substance use rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: students' concern about influenza
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: daily practice of NPIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endoscopic recurrence of Crohn's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thromboplastin Time (TT-SPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Spasticity measured by the Modified Ashworth Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SESS (Spasticity Evaluation Scale Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in pain and fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: total duration of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: duration of first stage of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: combined duration of first and second stages of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Prevalence of cervical cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of glucose values within target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of radiological deterioration of joint space
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: dynamic and isometric muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 6-month EFS
Endpoint domain: Mortality/survival
Primary endpoint: Drug-attributed grade 3/4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: total 5-RM strength gains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) values of venlafaxine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of O-desmethyl-venlafaxine (ODV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in natural killer (NK) cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in NK cell activity (NKCA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of neck recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Divided attention improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICU-acquired severe sepsis and septic shock
Endpoint domain: Adverse events/effects
Primary endpoint: anti-tetanus antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: patients' trust in their physician
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: duration of clinic visit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: self-reported musculoskeletal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: hSBA titres ≥1:4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: rSBA titres ≥1:8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Menstrual Blood Loss (MBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Haemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total care time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: ADL care time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Supervision time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in Conduct Problem scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration-time course of dipyrone metabolites in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Body Weight Loss (TBWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of contour classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: work‐to‐family conflict
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of life analysis
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cortisol levels after CRH stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ACTH levels after CRH stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: peri-implant marginal bone level changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean radiographic bone loss (mBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PANSS total score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI severity score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial emotion recognition performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual processing amplitudes (P100, N170, N250)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of gingivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction time for digit-symbol substitution test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of ST segment elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Averaged peak velocity 40 minutes after reperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Regional wall motion of the infarcted area three weeks after onset of AMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: days of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete resolution of heartburn or regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Platelet Reactivity Unit (PRU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High On-Treatment Reactivity (OTR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds of anaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Frequencies of MDR gram-negative pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Itch intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Frequency of scratching
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patient privacy concerns
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preference for TAA-AQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Expected compliance with TAA-AQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: patient comfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to reach the vocal folds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global ability
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: de novo development of CD8+ T cells responding to peptide-pulsed targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: de novo DTH (delayed-type hypersensitivity) priming
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in VLRs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: red blood cell concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: platelet concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: self-determined motivation for healthy lifestyles
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Heart failure hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to CR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes